Welcome to our dedicated page for Si-Bone news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on Si-Bone stock.
SI-BONE, Inc. (NASDAQ: SIBN) is a medical device company focused on minimally invasive surgical technologies for sacropelvic disorders, including sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, spinopelvic and sacropelvic fixation, and pelvic trauma. This news page aggregates company press releases and market updates related to SIBN stock and SI-BONE’s sacropelvic platform.
Investors following SI-BONE news can expect regular updates on quarterly and annual financial results, preliminary revenue announcements, and changes to financial guidance. Recent communications have highlighted double-digit worldwide and U.S. revenue growth, gross margin performance, adjusted EBITDA trends, and cash and cash equivalents. The company also reports operational metrics such as the number of active U.S. physicians using its technologies and revenue per sales territory.
Beyond earnings, SI-BONE’s news flow includes information on reimbursement developments, such as New Technology Add-on Payments and other payment designations for procedures involving products like iFuse TORQ TNT and iFuse Bedrock Granite. The company also issues 8-K-linked press releases covering leadership and board changes, including retirements, consulting agreements, and commercial leadership transitions.
Another recurring theme in SI-BONE news is participation in healthcare and medtech investor conferences hosted by firms such as Piper Sandler, Morgan Stanley, Canaccord Genuity, Truist Securities, and Goldman Sachs. These events often feature fireside chats or presentations where management discusses sacropelvic technologies, clinical evidence, and financial performance, with webcasts made available through the investors section of SI-BONE’s website.
For anyone tracking SIBN, this page offers a centralized view of SI-BONE’s earnings releases, preliminary updates, conference appearances, and other company announcements related to its sacropelvic surgical technology platform.
SI-BONE, a medical device company focused on sacropelvic disorders, will participate in two key events: the 7th Annual Truist Securities 2021 Life Sciences Summit on May 5, 2021, and the 2021 Bank of America Health Care Conference on May 12, 2021. During the Truist Securities event, management will host a Fireside Chat at 2:40 p.m. ET, and at the Bank of America Conference, they will present at 8:00 a.m. ET. Interested parties can view live and archived webcasts on the company’s website.
SI-BONE, Inc. (SIBN) announced significant leadership changes, appointing Anshul Maheshwari as Chief Financial Officer effective April 20, 2021. The transition also includes Laura Francis taking over as CEO, while Jeff Dunn remains Executive Chairman. Maheshwari brings over 15 years of experience, including his role at Varian Medical Systems. Additionally, Helen Loh and Laura Francis are new Board members, expected to enhance SI-BONE's strategy and marketing efforts. These changes aim to strengthen the company's growth and operational capabilities.
SI-BONE, Inc. (Nasdaq: SIBN) will report Q1 2021 financial results after market close on May 3, 2021. This announcement includes a conference call at 1:30 PM PT / 4:30 PM ET, accessible via phone or webcast on their website. The iFuse Implant System, the company's primary product for treating sacroiliac joint dysfunction, has shown positive clinical outcomes supported by multiple studies. Since 2009, iFuse has been the only SI joint fusion device with established insurance coverage based on its clinical effectiveness and safety.
SI-BONE, Inc. (Nasdaq:SIBN) reported financial results for Q4 and FY 2020, showcasing a 12% increase in Q4 revenue to $22.1 million and a 9% increase for the year to $73.4 million. U.S. revenue grew 10% to $68.1 million for 2020. The company expects 2021 revenue guidance of $92 million to $94 million, reflecting projected growth of 25% to 28%. Operating loss stood at $7.9 million for Q4 and $38.6 million for the year. Cash and securities totaled $196.4 million as of Dec 31, 2020. The company continues to navigate challenges posed by the COVID-19 pandemic.
SI-BONE, Inc. (Nasdaq: SIBN) will announce its financial results for Q4 and full year 2020 on March 8, 2021, after market closure. A conference call will follow at 1:30 PM PT, available via phone and webcast. The company specializes in innovative minimally invasive surgery for sacroiliac joint disorders, particularly with its iFuse Implant System, which is backed by numerous clinical studies highlighting its effectiveness. This press release underscores SI-BONE's commitment to addressing chronic low back pain issues, along with its established insurance coverage for the iFuse procedure.
SI-BONE, Inc. (SIBN) has appointed Laura Francis as Chief Executive Officer, succeeding Jeff Dunn, who transitions to Executive Chairman. Francis, previously CFO and COO, intends to focus on growth through enhancements in sales and new product development. Tony Recupero is promoted to President, Commercial Operations. Preliminary revenue for Q4 2020 is projected at $21.9-$22.2 million, marking an 11-12% increase year-over-year, while full-year revenue is expected between $73.1-$73.4 million, reflecting roughly 9% growth. However, potential COVID-19 impacts remain uncertain, and 2021 financial guidance is not provided.
SANTA CLARA, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (SIBN) announced that the International Society for the Advancement of Spine Surgery published its updated Policy on MIS Sacroiliac Joint Fusion. The policy supports the adoption of MIS SI joint fusion procedures, particularly the iFuse Procedure, based on high-level clinical evidence for its safety and effectiveness. The ISASS does not recommend MIS posterior SI joint fusion due to inadequate clinical evidence. This update provides crucial guidance for clinicians and payors regarding the iFuse Implant System.
SI-BONE, Inc. announced that as of November 25, 2020, Priority Health Michigan became the 36th U.S. payor to adopt an exclusive, positive coverage policy for the iFuse Implant System, which is used in minimally invasive sacroiliac joint fusion surgeries. This new policy covers treatments related to lower back pain specifically for sacroiliac joint disorders. Furthermore, the Blue Cross Blue Shield Association updated its evidence rating to endorse triangular implants, affirming their efficacy compared to other systems. This change is supported by over 85 peer-reviewed studies.
SI-BONE, Inc. (Nasdaq: SIBN) announced participation in two major healthcare conferences: the 23rd Annual Needham Growth Conference and the 39th Annual J.P. Morgan Healthcare Conference. Management will engage in a Fireside Chat on January 11, 2021, at 2:45 p.m. ET and will present on January 14, 2021, at 2:50 p.m. ET. Both events will be accessible via live and archived webcasts on the company's website. SI-BONE specializes in minimally invasive surgery for sacropelvic disorders, with its iFuse Implant System backed by extensive clinical studies.
SI-BONE, Inc. (SIBN) announced that Humana, one of the largest U.S. commercial payers, has revised its coverage policy to include minimally invasive sacroiliac joint fusion using the iFuse Implant System. This update, effective December 10, 2020, allows coverage for chronic low back pain due to sacroiliac joint dysfunction, contingent on meeting specific criteria. Humana joins 36 other health plans covering iFuse procedures, which are supported by multiple clinical studies demonstrating efficacy in pain relief and improved quality of life.